Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib Plus Chemotherapy in Unresectable Stage III ALK+ NSCLC
NCT07573696Phase 2Not yet recruiting
- Start
- Jun 2026
- Primary completion
- Feb 2030
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of alectinib in non-small cell lung cancer (NSCLC). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07573696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07573696.